<DOC>
	<DOCNO>NCT01807468</DOCNO>
	<brief_summary>To evaluate feasibility efficacy haploidentical stem cell transplantation patient high-risk solid tumor fail tandem high-dose chemotherapy autologous stem cell transplantation . To evaluate feasibility efficacy NK cell infusion haploidentical stem cell transplantation patient high-risk solid tumor fail tandem high-dose chemotherapy autologous stem cell transplantation .</brief_summary>
	<brief_title>Haploidentical Stem Cell Transplantation NK Cell Therapy Patients With High-risk Solid Tumors</brief_title>
	<detailed_description>HaploSCT follow reduced-intensity conditioning ( RIC ) regimen perform patient high-risk solid tumor . Both parent evaluate KIR genotype phenotype one great degree KIR-L mismatch patient select donor . In addition , ex-vivo expand NK cell derive donor administer haploSCT increase GVT effect . Low-dose IL-2 give expand NK cell infusion enhance NK cell alloreactivity .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Sarcoma , Ewing</mesh_term>
	<mesh_term>Osteosarcoma</mesh_term>
	<mesh_term>Rhabdomyosarcoma</mesh_term>
	<criteria>age &lt; 21 year old Patients highrisk solid tumor fail prior HDCT/autoSCT Patients suitable haploidentical donor Highrisk solid tumor include highrisk neuroblastoma , metastatic relapse Ewing sarcoma , relapse osteosarcoma , highrisk brain tumor , relapse germ cell tumor , relapse soft tissue sarcoma , relapse rhabdomyosarcoma , etc . stable disease salvage chemotherapy relapse organ dysfunction ( NCI common toxicity criterion grade &gt; 2 ) progression disease despite salvage chemotherapy</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>haploidentical stem cell transplantation</keyword>
	<keyword>natural killer cell therapy</keyword>
	<keyword>pediatric solid tumor</keyword>
</DOC>